US Patent

US11759504 — PTH compounds with low peak-to-trough ratios

Formulation · Assigned to Ascendis Pharma Bone Diseases AS · Expires 2037-09-28 · 11y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition of a PTH compound with a pharmacokinetic profile that has a peak to trough ratio of less than 4 after subcutaneous administration.

USPTO Abstract

The present invention relates to a pharmaceutical composition comprising a PTH compound, wherein after subcutaneous administration the pharmacokinetic profile of the PTH compound exhibits a peak to trough ratio of less than 4 within one injection interval.

Drugs covered by this patent

Patent Metadata

Patent number
US11759504
Jurisdiction
US
Classification
Formulation
Expires
2037-09-28
Drug substance claim
No
Drug product claim
Yes
Assignee
Ascendis Pharma Bone Diseases AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.